Gram-Negative

Bacteroides fragilis Infection Models

In vivo efficacy testing against Bacteroides fragilis, the leading anaerobe of intra-abdominal abscess and the most antibiotic-resistant of the anaerobes, in an abscess model.

Bacteroides fragilis (B. fragilis) is an obligately anaerobic, Gram-negative rod and a dominant member of the normal colonic flora. It is also the anaerobe most frequently recovered from clinical infection – disproportionately so, since it makes up only a small fraction of gut bacteria but accounts for a large share of serious anaerobic disease. When B. fragilis escapes the gut through surgery, perforation, or trauma, it causes intra-abdominal and other deep-tissue abscesses and bloodstream infection.

Abscess formation is its signature: the organism’s capsular polysaccharide is itself sufficient to provoke abscesses, through a host immune response to the capsule, which sets B. fragilis apart from most other gut bacteria. It is also the most resistant of the anaerobes – of all anaerobic pathogens, the genus Bacteroides carries the highest rates of antibiotic resistance, and B. fragilis both resists treatment and serves as a reservoir of resistance genes for the wider gut flora.

TransPharm Preclinical Solutions evaluates candidates against B. fragilis in an abscess model and produces the quantitative efficacy data an anti-anaerobic program needs.

Scientific Scope

The scientific problem in a B. fragilis study begins with the fact that it is a strict anaerobe, which shapes the model and every step of handling – challenge, recovery, and susceptibility testing all have to be done under anaerobic conditions. Its disease is distinctive too: because the capsular polysaccharide drives abscess formation, the abscess is both the clinical hallmark and the natural readout for efficacy. Strain choice follows the development question – a reference isolate such as the type strain ATCC 25285 (NCTC 9343) supports standard abscess and burden studies, while a carbapenem-resistant (cfiA), metronidazole-resistant (nim), or enterotoxigenic (bft-positive) isolate is the relevant challenge for a candidate positioned against resistant or toxin-driven disease.

Intra-abdominal infection is also frequently polymicrobial, mixing anaerobes with facultative organisms, which is a further design consideration. TransPharm Preclinical Solutions maintains an on-site library of hundreds of validated pathogens and can source or validate characterized B. fragilis isolates, including defined resistant phenotypes, to a program’s specifications.

Validated Infection Models

Every study parameter is configurable to the scientific question: challenge strain, host species and strain, route of administration, comparator agents, and dosing schedule. The core readouts are abscess formation and quantitative bacterial burden (CFU) at the infected site and in harvested tissues, with the supporting measures a program requires.

The following are available as add-ons to any study:

  • Pharmacokinetic profiling and PK/PD analysis
  • Blood chemistry
  • Additional tissue harvests
  • Histopathology

Abscess

The abscess model reproduces the deep-tissue and intra-abdominal abscess that is the hallmark of B. fragilis infection. Consistent with the established models of B. fragilis abscess, the organism is introduced so that its capsular polysaccharide drives abscess formation, and the readout is abscess development together with bacterial burden at the site – the measures on which an anti-anaerobic candidate is judged. The model suits agents developed for intra-abdominal and other anaerobic abscess disease. Because this model is not yet detailed on the current site, its host species, the challenge and any adjuvant conditions, and the specific endpoints are confirmed at protocol design.

In Vitro Susceptibility Testing

In vitro susceptibility testing complements the in vivo model, and for an anaerobe it follows the anaerobic reference methodology – agar dilution per CLSI M11. This is where B. fragilis‘s characteristic resistances – β-lactamase production, carbapenem resistance, and the metronidazole resistance that is rare but critical to detect – are characterized, and it can be paired with time-kill and combination analysis for a candidate’s profile.

Antimicrobial Resistance

Bacteroides fragilis is the reference point for antibiotic resistance among anaerobes, and its resistances are layered. Nearly all isolates produce the chromosomal β-lactamase encoded by cepA, which hydrolyzes penicillins and most cephalosporins and makes penicillin essentially useless against the organism; cfxA adds cefoxitin resistance. Carbapenem resistance – still uncommon but increasing – is conferred by the cfiA gene, a chromosomal metallo-β-lactamase that reaches high-level resistance when activated by an upstream insertion sequence. Clindamycin resistance, through erm genes, is now common, and multidrug efflux pumps broaden the picture further.

Most concerning is metronidazole resistance: metronidazole is the first-line drug for anaerobic infection and remains active against the great majority of isolates, but resistance mediated by nim genes has been reported and, because it threatens the mainstay of therapy, matters out of proportion to its current prevalence. Carbapenems, metronidazole, and β-lactam/β-lactamase-inhibitor combinations remain the backbone of treatment – which is exactly why the resistance profile of the challenge strain determines what an efficacy study can claim.